Valneva Investor Relations Program
In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.
In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.
The Process
LifeSci performed the following activities which brought investors into the stock and ultimately led to a successful NASDAQ dual-listing:
- Aggressive outreach to new investors and sell-side analysts
- Arranged 15 meetings during the 2021 LifeSci Corporate Access Event
- Worked with management to strengthen messaging and optimize competitive positioning for VLA2001 and other pipeline programs
- Provided capital markets support throughout the process, including through banker selection and 80 TTW and IPO roadshow meetings
- Achieved numerous high-profile media placements, including in the New York Times, Bloomberg, Fortune, FierceBiotech, BioWorld, Pharmafocus
The Results
On May 6, 2021, Valneva successfully completed its NASDAQ IPO and concurrent global offering consisting of a combined US public offering and European private placement in the aggregate of $107.6 million, after full exercise of the overallotment option. Goldman Sachs, Jefferies, Guggenheim and Bryan Garnier acted as joint bookrunners for the offering.